Merck Stock Forecast for 2023 - 2025 - 2030

Updated on 03/24/2023

Stock Rating
5
Price Target
$118.00
Consensus
Outperform
Upside
13.25%
Analysts
15
Stock Rating
5
Upside
13.25%
Analysts
15
Price Target
$118.00

Merck Stock Forecast and Price Target

The average price target of $118.00 for Merck's stock set by fiveteen distinguished analysts in recent weeks would represent a potential upside of approximately 13.25% from the last closing price in March, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $136.00 and a low estimate of $97.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.

$118.00

13.25% Upside

Outperform
Outperform

Merck Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Merck's Price has grown, increasing from $71.99 to $83.50 – a growth of 15.99%. The next year looks promising for Merck, with analysts predicting Fair Value of $100.42 – an increase of 20.27%. Over the next eight years, experts anticipate that Merck's Fair Value will grow at a rate of 25.91%.

2023 Fair Value Forecast
$100.42
2024 Fair Value Forecast
$114.98
2025 Fair Value Forecast
$126.63
2026 Fair Value Forecast
$135.09
2027 Fair Value Forecast
$148.69
2028 Fair Value Forecast
$159.23
2029 Fair Value Forecast
$127.88
2030 Fair Value Forecast
$105.13
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$151.06 $181.05 19.49%
LLY Stock Forecast Eli Lilly and Outperform 16
$332.53 $333.19 20.29%
PFE Stock Forecast Pfizer Inc Outperform 3
$40.16 $53.97 31.10%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$66.96 $80.99 23.95%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$801.75 $796.73 -2.46%

Merck Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Merck's Revenue has grown, increasing from $46.84B to $48.70B – a growth of 3.98%. The next year looks promising for Merck, with analysts predicting Revenue of $55.63B – an increase of 14.21%. Over the next eight years, experts anticipate that Merck's Revenue will grow at a rate of 5.67%.

2023 Rev Forecast
$55.63B
2024 Rev Forecast
$58.09B
2025 Rev Forecast
$61.50B
2026 Rev Forecast
$63.75B
2027 Rev Forecast
$65.57B
2028 Rev Forecast
$66.95B
2029 Rev Forecast
$57.16B
2030 Rev Forecast
$51.46B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 16
$304.73 $323.74 6.98%
ZTS Stock Forecast Zoetis Outperform 18
$161.12 $209.70 27.23%
BAX Stock Forecast Baxter International Inc Outperform 17
$38.12 $60.73 52.15%

Merck Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, Merck's Dividend per Share has grown by 18.18%, from $2.20 to $2.60. For the next year, analysts are expecting Dividend per Share to reach $3.01 – an increase of 15.77%. Over the next eight years, experts predict that Dividend per Share will grow by 23.08%.

2023 DPS Forecast
$3.01
2024 DPS Forecast
$3.27
2025 DPS Forecast
$3.48
2026 DPS Forecast
$3.60
2027 DPS Forecast
$4.04
2028 DPS Forecast
$4.29
2029 DPS Forecast
$3.20
2030 DPS Forecast
$3.20
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$190.64 $244.18 31.66%
VTRS Stock Forecast Viatris Hold 8
$9.44 $13.70 43.01%
UTHR Stock Forecast United Therapeutics Outperform 12
$216.09 $280.69 36.52%

Merck Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Merck's Free Cash Flow has fallen from $9.97B to $9.66B – a 3.07% decrease. For next year, analysts predict Free Cash Flow of $16.98B, which would mean an increase of 75.75%. Over the next eight years, experts predict that Merck's Free Cash Flow will grow at a rate of 64.45%.

2023 FCF Forecast
$16.98B
2024 FCF Forecast
$18.83B
2025 FCF Forecast
$18.99B
2026 FCF Forecast
$19.57B
2027 FCF Forecast
$20.04B
2028 FCF Forecast
$20.24B
2029 FCF Forecast
$18.90B
2030 FCF Forecast
$15.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$62.64 $83.92 16.54%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$33.62 $52.42 48.72%
CYTK Stock Forecast Cytokinetics Outperform 10
$33.63 $62.67 78.41%

Merck Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Merck's Net Income has grown from $9.84B to $13.05B – a 32.57% increase. Next year, analysts are expecting Net Income to reach $18.11B – an increase of 38.81%. Over the next eight years, the forecast is for Net Income to grow by 29.43%.

2023 NI Forecast
$18.11B
2024 NI Forecast
$20.63B
2025 NI Forecast
$22.38B
2026 NI Forecast
$23.48B
2027 NI Forecast
$25.38B
2028 NI Forecast
$26.54B
2029 NI Forecast
$20.81B
2030 NI Forecast
$16.89B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$121.28 $163.67 35.22%
NEOG Stock Forecast Neogen Hold 16
$18.29 $37.00 39.42%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$21.12 $0.00 39.68%

Merck EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Merck's EBITDA has grown by 3.31%, rising from $18.37B to $18.98B. For next year, analysts predict EBITDA of $23.74B, which would mean an increase of 25.07%. In 2030, professionals predict that Merck's EBITDA will decrease by 3.86%, to $18.25B.

2023 EBITDA Forecast
$23.74B
2024 EBITDA Forecast
$26.32B
2025 EBITDA Forecast
$28.06B
2026 EBITDA Forecast
$29.25B
2027 EBITDA Forecast
$31.55B
2028 EBITDA Forecast
$30.36B
2029 EBITDA Forecast
$22.16B
2030 EBITDA Forecast
$18.25B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$14.91 $73.38 27.43%
INDV Stock Forecast Indivior PLC Buy 14
£182.80 £3.79 -97.41%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$38.60 $79.67 102.07%

Merck EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Merck's EBIT has grown, rising from $14.95B to $15.86B – a growth of 6.05%. In the next year, analysts believe that EBIT will reach $21.25B – an increase of 34.03%. For the next eight years, the forecast is for EBIT to grow by 23.04%.

2023 EBIT Forecast
$21.25B
2024 EBIT Forecast
$24.18B
2025 EBIT Forecast
$25.78B
2026 EBIT Forecast
$27.27B
2027 EBIT Forecast
$29.56B
2028 EBIT Forecast
$29.96B
2029 EBIT Forecast
$24.15B
2030 EBIT Forecast
$19.51B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$36.91 $41.00 19.21%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$10.51 $12.60 18.93%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$35.00 $35.50 -2.86%

Merck EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Merck's EPS has grown, increasing from $5.19 to $6.02 – a growth of 15.99%. The next year looks promising for Merck, with analysts predicting EPS of $7.24 – an increase of 20.27%. Over the next eight years, experts anticipate that Merck's EPS will grow at a rate of 25.91%.

2023 EPS Forecast
$7.24
2024 EPS Forecast
$8.29
2025 EPS Forecast
$9.13
2026 EPS Forecast
$9.74
2027 EPS Forecast
$10.72
2028 EPS Forecast
$11.48
2029 EPS Forecast
$9.22
2030 EPS Forecast
$7.58
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$68.49 $195.43 131.42%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$231.96 $170.08 -24.56%
USNA Stock Forecast USANA Health Sciences Hold 14
$60.51 $104.00 -5.80%